All Stories

  1. Rare Case of Young Cardiac Amyloidosis: Difficult Diagnostic Pathway in Routine Clinical Care
  2. Automatic Disposable Microfluidic Cartridge System for ELISA on Microbeads with Electrochemical Detection
  3. Cardiac amyloidosis: consensus of the Eurasian Association of Cardiologists (EAC)
  4. Efficacy and Safety of Sglt-2 Inhibitors In Renal Allograft Recipients: an Open-Label, Single-Center Prospective Study
  5. The Effectiveness and Profitability of Different Antithrombotic Therapy Regimens in Patients with Type 2 Diabetes Mellitus During 1 Year of Follow-Up after an Exacerbation of Coronary Heart Disease According to the Study ORACLE II
  6. The prevalence of pathogenic variants in the BMPR2 gene in patients with the idiopathic pulmonary arterial hypertension in the Russian population: sequencing data and meta-analysis
  7. Malignancies after kidney transplantation: results of a 34-year population-based study
  8. Severely Ill COVID-19 Patients May Exhibit Hypercoagulability Despite Escalated Anticoagulation
  9. Risk factors for new-onset diabetes after transplantation in kidney transplant recipients: own data and meta-analysis
  10. Critically Ill COVID-19 Patients May Exhibit Plasma Hypercoagulability Despite Escalated Anticoagulation
  11. Clinical Features and Prospective Outcomes of Thin-Filament Hypertrophic Cardiomyopathy: Intrinsic Data and Comparative Insights from Other Cohorts
  12. Which scale is best to assess the risk of upper gastrointestinal bleeding in patients with stable coronary artery disease in the Russian population?
  13. Predictive value of left ventricular global function index in patients with aortic stenosis
  14. Clinical and Genetic Landscape Hypertrophic Cardiomyopathy on a Russian Single-Center Cohort Study
  15. Cardiology 2023: the time of genetics
  16. Assessment and modification of cardiovascular risk in non-cardiac surgery. Clinical guidelines 2023
  17. Assessment and modification of cardiovascular risk in non-cardiac surgery. Clinical guidelines 2023
  18. Results of a pilot clinical trial of the safety and efficacy of an original glycoprotein IIb/IIIa receptor inhibitor in acute coronary syndrome
  19. Incidence of familial hypercholesterolemia in patients with early manifestations of coronary artery disease: data from a Russian multicenter study and meta-analysis
  20. Lipoprotein (a) as a marker of hereditary lipid metabolism disorders in patients with early manifestation of coronary artery disease
  21. A rare variant in the TTR gene (p.E112K) is associated with systemic amyloidosis and a new symptom – skin hyperemia in response to ethanol intake: family segregation analysis, literature review, and a clinical case. Case report
  22. The levels of certain circulating microRNAs in hypertrophic cardiomyopathy are associated with echocardiographic parameters
  23. Mortality among kidney transplant recipients with SARS-CoV-2: a systematic review and meta-analysis of cohorts and clinical registries
  24. Mortality in kidney transplant recipients: a systematic review and meta-analysis of cohorts and clinical registries
  25. Novel Genes Involved in Hypertrophic Cardiomyopathy: Data of Transcriptome and Methylome Profiling
  26. Overlapping Phenotype of Adult-Onset ALPK3-Cardiomyopathy in the Setting of Two Novel Variants
  27. A survey of physician opinions in Russia in the field of pharmacogenetics of cardiovascular disease
  28. Left ventricular global function index and peculiarities of daily blood pressure profile in patients with arterial hypertension
  29. Molecular cardiology: from decoding the genetic nature and mechanisms of the diseases development to the introduction into the clinic
  30. Practical guidelines for the diagnosis and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM or transthyretin cardiac amyloidosis)
  31. Prospects for Using Chromatography–Mass Spectrometry for the Determination of Lipids in Clinical Cardiolipidology
  32. Circulating miR-499a-5p Is a Potential Biomarker of MYH7—Associated Hypertrophic Cardiomyopathy
  33. Сonsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy
  34. Left ventricular global function index as a predictor of adverse cardiovascular events in patients with acute coronary syndrome
  35. Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy
  36. Visit-to-visit blood pressure variability in patients after acute coronary syndrome
  37. Changes in plasma sphingolipid levels against the background of lipid-lowering therapy in patients with premature atherosclerosis
  38. Pitavastatin: focus on safety and drug interactions
  39. Prevalence of hereditary factors in different age groups in patients with acute coronary syndrome
  40. Risk Stratification after an Acute Coronary Syndrome: Significance of Antithrombotic Therapy
  41. Using the ORACLE Risk Score to Assess Hemorrhagic Risk in Patients with Acute Coronary Syndrome and Atrial Fibrillation
  42. RESULTS OF MULTICENTER MONITORING OF HEMOSTASIS PARAMETERS IN PATIENTS WITH COVID-19
  43. 2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction
  44. 2020 Clinical practice guidelines for Chronic heart failure
  45. Bleeding risk scales in patients with acute coronary syndrome: place of the ORACUL scale
  46. Can left ventricular global function index be a novel marker of unfavorable outcome in patients with acute coronary syndrome
  47. Contribution of electrocardiography to the diagnosis of cardiomyopathies and athletic heart syndrome
  48. Inherited thrombophilia and venous thromboembolism: testing rules in clinical practice
  49. Changes in the management of patients with acute coronary syndrome – have the disease outcomes changed?
  50. The Risk of Developing Ischemic Stroke in Patients After Exacerbation of Ischemic Heart Disease
  51. Recommendations of the Eurasian Arrhythmology Association (EURA) for the diagnosis and treatment of patients with arrhythmias and conduction disorders during the COVID-19 pandemic
  52. CYP2C9 and VKORC1 genotyping for the quality of long-standing warfarin treatment in Russian patients
  53. Bleeding rate and diagnostic value of different hemorrhagic risk scores in certain clinical groups of patients with acute coronary syndrome
  54. Cardiology: genetics’ time
  55. Lipidome features in patients with different probability of family hypercholesterolemia
  56. External validation of the ORACLE bleeding risk score using the database of the RECORD 3 registry
  57. Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF
  58. Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation
  59. Place of Prasugrel, P2Y12 receptor antagonist, in an early invasive treatment of patients with acute coronary syndrome (according to the results of multicenter randomized controlled trial ISAR-REACT 5)
  60. A clinical case of hypertrophic cardiomyopathy and family hyperlipidemia
  61. THE FREQUENCY OF CARDIOVASCULAR EVENTS AFTER ACS IN PATIENTS WITH DIFFERENT ADHERENCE TO THERAPY (data from a prospective study)
  62. Ticagrelor in Patients with Stable Coronary Disease and Diabetes
  63. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial
  64. Participation of Sphingolipids in the Pathogenesis of Atherosclerosis
  65. Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF
  66. VISIT-TO-VISIT BLOOD PRESSURE VARIABILITY AND RISK OF ALL-CAUSE DEATH
  67. Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation
  68. Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes
  69. Bleeding risk factors in patients with acute coronary syndrome: data from observational studies ORACUL II
  70. Physicians' guideline adherence is associated with long‐term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry
  71. Rationale, Design, and Baseline Characteristics of THEMIS: Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study
  72. Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry
  73. Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation
  74. Psychosomatic Disorders in Patients with Pulmonary Hypertension: Impact on Treatment Adherence
  75. Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry
  76. Risk Profile and 1-Year Outcome of Newly Diagnosed Atrial Fibrillation in Japan ― Insights From GARFIELD-AF ―
  77. Polymorphism of TNF gene in acute coronary syndrome patients: data from the registries ORACLE I and ORACLE II
  78. Targeted sequencing in patients with clinically diagnosed hereditary lipid metabolism disorder and acute coronary syndrome
  79. Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry
  80. Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registry
  81. Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial
  82. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness
  83. Screening of familial hypercholesterolemia among patients in age under 40 years old exposed by duplex scanning of carotid arteries, by the local registry data
  84. Polymorphism of ANXA2 gene may accelerate vulnerability and calcinosis in patients with coronary atherosclerosis
  85. IL-10 GENE POLYMORPHISM AND STROKE RISK IN PATIENTS WITH CORONARY ARTERY DISEASE
  86. STRATEGY TO MINIMIZE THE BLEEDING RISKS IN PATIENTS WITH ATRIAL FIBRILLATION WHO RECEIVE COMBINED ANTITHROMBOTIC THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION
  87. Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME®
  88. Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants
  89. GENETIC MARKERS OF MYOCARDIAL FIBROSIS: OPPORTUNITY TO PREDICT ADVERSE OUTCOMES IN AORTIC STENOSIS
  90. IS IT SAFE TO SWITCH OAC IN PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION? RESULTS FROM A RE-DUAL PCI SUBANALYSIS
  91. Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation
  92. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
  93. Family History of Cardiovascular Disease in Patients With Early Development of Acute Coronary Syndrome
  94. Possibilities of molecular biopsy in differential diagnosis of pulmonary arterial hypertension: case description and literature review
  95. Risk of Stroke After Exacerbation of Ischemic Heart Disease: Data of 3‑Years Follow-up
  96. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial
  97. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
  98. Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry
  99. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation
  100. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries
  101. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
  102. [PP.30.09] KIF6 GENE POLYMORPHISM IS ASSOCIATED WITH ARTERIAL RESISTANCE AND ATHEROSCLEROSIS IN PATIENTS WITH HYPERTENSION
  103. Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF‐TIMI 48 Trial
  104. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
  105. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
  106. Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
  107. Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves
  108. Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry
  109. Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease ― Results From EMPA-REG OUTCOME® ―
  110. OUP accepted manuscript
  111. OUP accepted manuscript
  112. GENETIC POLYMORPHISM OF THE INFLAMMATORY CYTOKINE GENES AND ARTERIAL WALL PROPERTIES IN HYPERTENSIVE PATIENTS
  113. PRIMARY (GENETICALLY DETERMINED) DILATION CARDIOMYOPATHY IN A PATIENT WITH NOVEL MUTATION OF LAMIN GENE: CLINICAL AND MORPHOLOGICAL MANAGEMENT
  114. Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation
  115. Evolving quality standards for large-scale registries: the GARFIELD-AF experience
  116. Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry
  117. Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry
  118. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation
  119. Multiple coronary fistulae into left ventricle as a rare cause of myocardial ischemia
  120. [PP.07.21] PARG GENE POLYMORPHISM IS ASSOCIATED THE DEVELOPMENT OF LEFT VENTRICULAR HYPERTROPHY IN ARTERIAL HYPERTENSION
  121. Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events
  122. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
  123. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF
  124. A Novel Hypoxia-Inducible Factor−Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial
  125. Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists
  126. Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48
  127. The use of optimal partitionings for multiparameter data analysis in clinical trials
  128. Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF
  129. Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction With ST-Segment Elevation After Prehospital Thrombolysis
  130. Using Necrosis Biomarkers for the Early Diagnosis of Myocardial Infarction in Modern Conditions
  131. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial
  132. Early Systolic Dysfunction of Left Ventricular Myocardium Is Reflected On Electrocardiogram of Patients With Aortic Stenosis
  133. Genetic Features of Factors of Inflammation and Fibrosis – Possible Common Pathway of Formation of Predisposition to Atrial Fibrillation and Chronic Obstructive Pulmonary Disease
  134. MOLECULAR-GENETIC FACTORS, ASSOCIATED WITH AORTIC STENOSIS DEVELOPMENT
  135. Atrial Fibrillation in Patients With Chronic Obstructive Pulmonary Disease Is Associated With Polymorphism of Interleukin 6 Gene
  136. GENETIC POLYMORPHISM OF INFLAMMATORY FACTORS IS ASSOCIATED WITH THROMBOEMBOLIC COMPLICATIONS OF ATRIAL FIBRILLATION
  137. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
  138. THE REVOLUTION, WE HAVE ALMOST OVERSLEPT
  139. Arterial Hypertension Complicated by Myocardial Hypertrophy and Heart Failure Is Associated With Lower Serum Levels of Vascular Endothelium Growth Factor (VEGF-A165)
  140. Biomarkers in Heart Failure: Apelin Level Is not Associated With Presence and Severity of the Disease
  141. Does Sex Affect Anticoagulant Use for Stroke Prevention in Nonvalvular Atrial Fibrillation?: The Prospective Global Anticoagulant Registry in the FIELD-Atrial Fibrillation
  142. Late Silent Stent Abscess
  143. Chronic Thromboembolic Pulmonary Hypertension
  144. Current Aspects of Fibrinolysis
  145. Сhronic Thromboembolic Pulmonary Hypertension
  146. Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome
  147. Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin
  148. An intuitive risk factors search algorithm: usage of the Bayesian network technique in personalized medicine
  149. Laboratory Monitoring of the Efficacy and Safety of Anticoagulants
  150. Degenerative Aortic Stenosis: Prediction of Poor Prognosis by 2D Left Ventricular Longitudinal Strain in Non-Operated Patients
  151. Dabigatran in Prevention of Stroke in Atrial Fibrillation: Three Years of Clinical Application
  152. Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome
  153. Edoxaban versus Warfarin in Patients with Atrial Fibrillation
  154. Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization
  155. ISSUES OF ANTICOAGULANT TREATMENT MANAGEMENT
  156. WARFARIN IN PATIENTS WITH CARDIOEMBOLIC STROKE
  157. Polymorphic markers Ala455Val of the THBD gene and Arg353Gln of the F7 gene and genetic association with unfavorable outcomes of coronary atherosclerosis in patients with a history of acute ischemic heart disease
  158. Rationale, design, and results from RENO-DEFEND 1: A randomized, dose-finding study of the selective A1 adenosine antagonist SLV320 in patients hospitalized with acute heart failure
  159. 602 ASSOCIATION OF POLYMORPHIC MARKERS C3386A OF HMGCR GENE AND G(-198)A OF FDFT1 GENE WITH CORONARY ARTERY DISEASE
  160. 611 DEVELOPMENT OF GENDER PRESPECIFIED PREDICTION MODEL BASED ON BAYESIAN BELIEVE NETWORKS METHOD FOR RISK ESTIMATION AFTER ACUTE CORONARY SYNDROME
  161. 869 DEVELOPMENT OF GENDER PRESPECIFIED PREDICTIVE MODEL BASED ON BAYESIAN BELIEVE NETWORKS METHOD FOR UNFAVOURABLE OUTCOMES AFTER ACUTE CORONARY SYNDROME
  162. 634 GENDER DEPENDENT ASSOCIATION BETWEEN KIF6 POLYMORPHISM AND RISK OF UNFAVORABLE OUTCOME IN PATIENTS SURVIVED ACUTE CORONARY SYNDROME
  163. 639 POLYMORPHIC MARKERS OF THBD AND PROC GENES AND GENETIC PREDISPOSITION TO UNFAVOURABLE OUTCOMES IN PATIENTS AFTER ACUTE CORONARY SYNDROME
  164. Ispol'zovanie rozuvastatina v lechenii bol'nykh gruppy riska sosudistykh oslozhneniy ateroskleroza.
  165. PECULIAR PROPERTIES OF ANTITHROMBOTIC THERAPY IN PATIENTS WITH ARTERIAL HYPERTENSION. IS IT POSSIBLE TO DO THE TREATMENT SAFE?
  166. Rolofylline, an Adenosine A1−Receptor Antagonist, in Acute Heart Failure
  167. The polymorphisms G(−174)C in IL6 gene and G(−1082)A in IL10 gene are associated with poor outcomes in patients with acute coronary syndrome
  168. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial
  169. Association of the polymorphic markers G(−455)A in the FGB gene and C(−1654)T in the PROC gene with hereditary predisposition to unfavourable outcome in patients with history of acute coronary syndrome
  170. MS217 ASSOCIATION OF THE CHOLESTEROL ESTER TRANSFER PROTEIN GENE (CETP) WITH CORONARY ARTERY DISEASE
  171. MS216 IL6 AND IL10 GENES ARE ASSOCIATED WITH UNFAVOURABLE OUTCOMES IN PATIENTS WITH ACUTE CORONARY SYNDROME
  172. Association of the CYBA, PPARGC1A, PPARG3, and PPARD gene variants with coronary artery disease and metabolic risk factors of coronary atherosclerosis in a Russian population
  173. Advanced age, low left atrial appendage velocity, and Factor V promoter sequence variation as predictors of left atrial thrombosis in patients with nonvalvular atrial fibrillation
  174. Design and Rationale of the PROTECT Study: A Placebo-controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effe...
  175. THE MODERN ASPECTS OF CLOPIDOGREL USE
  176. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
  177. Chronic Thromboembolic Pulmonary Hypertension
  178. The PROTECT Pilot Study: A Randomized, Placebo-Controlled, Dose-Finding Study of the Adenosine A1 Receptor Antagonist Rolofylline in Patients With Acute Heart Failure and Renal Impairment
  179. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial
  180. Safety and Efficacy of Outpatient Nesiritide in Patients With Advanced Heart Failure
  181. The BEAUTIFUL Study: Randomized Trial of Ivabradine in Patients with Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction – Baseline Characteristics of the Study Population
  182. Association of GNB3 gene C825T polymorphism with coronary heart disease
  183. Association ofCYP2D6andADRB1genes with hypotensive and antichronotropic action ofbetaxololin patients with arterial hypertension
  184. Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes
  185. Mo-P6:387 Genetic predisposition to early onset of coronary artery disease in Russian patients
  186. Mo-P6:455 Genetic predisposition to unfavourable outcomes in patients with unstable angina
  187. W03-P-008 Genetic basis of inherited predisposition to coronary artery disease
  188. Association of Polymorphic Marker A1/A2 of Gene ITGB3 with Coronary Artery Disease and Myocardial Infarction
  189. Association of Polymorphic Marker G(–455)A of Gene FGB with Coronary Artery Disease
  190. ASSOCIATION OF THE POLYMORPHIC MARKERS OF MTHFR, EDN1, CYP11B2, PPARA AND PPARG2 GENES WITH THE SEVERITY OF ESSENTIAL HYPERTENSION
  191. Anticoagulant properties of the endothelium studied by the standard venous occlusion test